vTv Therapeutics Inc
NASDAQ:VTVT

Watchlist Manager
vTv Therapeutics Inc Logo
vTv Therapeutics Inc
NASDAQ:VTVT
Watchlist
Price: 13.5723 USD -1.71% Market Closed
Market Cap: 40.9m USD
Have any thoughts about
vTv Therapeutics Inc?
Write Note

Net Margin
vTv Therapeutics Inc

-1 830.6%
Current
-38 367%
Average
-7.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 830.6%
=
Net Income
-18.3m
/
Revenue
1m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
vTv Therapeutics Inc
NASDAQ:VTVT
43.3m USD
-1 831%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
317.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
139.4B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
114.5B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.6B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
136.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.5B EUR
-5%
Country US
Market Cap 43.3m USD
Net Margin
-1 831%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 317.1B USD
Net Margin
9%
Country US
Market Cap 139.4B USD
Net Margin
13%
Country US
Market Cap 114.5B USD
Net Margin
0%
Country US
Market Cap 104.6B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 136.7B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.5B EUR
Net Margin
-5%
No Stocks Found

vTv Therapeutics Inc
Glance View

Market Cap
43.3m USD
Industry
Biotechnology

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 9 full-time employees. The company went IPO on 2015-07-30. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non- central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Nrf2/Bach1 Modulator Program.

VTVT Intrinsic Value
5.9179 USD
Overvaluation 56%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 830.6%
=
Net Income
-18.3m
/
Revenue
1m
What is the Net Margin of vTv Therapeutics Inc?

Based on vTv Therapeutics Inc's most recent financial statements, the company has Net Margin of -1 830.6%.